Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077451 · ClinicalTrials.gov registry record · Phase 2
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03077451 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 36 participants.
The verdict
NCT03077451, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Nelfinavir Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03077451
The ClinicalTrials.gov registry entry for NCT03077451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03077451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03077451 about?
NCT03077451 is a clinical study titled "Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma". This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT03077451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2017-03-13. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT03077451?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nelfinavir Mesylate (DRUG).
Who is sponsoring clinical trial NCT03077451?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.